MIRA INFORM REPORT

 

 

Report Date :

17.07.2012

 

IDENTIFICATION DETAILS

 

Name :

SIZA INTERNATIONAL (PVT) LIMITED

 

 

Registered Office :

18 K.M. Main Ferozepur Road, Lahore

 

 

Country :

Pakistan

 

 

Date of Incorporation :

1978

 

 

Com. Reg. No.:

0006462

 

 

Legal Form :

Private Limited Company

 

 

Line of Business :

Manufacture & Marketing of Pharmaceutical Products

 

 

No. of Employees :

180

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

Payment Behaviour :

No complaints

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st, 2012

 

Country Name

Previous Rating

(31.12.2011)

Current Rating

(31.03.2012)

Pakistan

B2

B2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D


Business Name

 

SIZA INTERNATIONAL (PVT) LIMITED

 

 

Full Address

 

Registered Address

18 K.M. Main Ferozepur Road, Lahore, Pakistan

 

Tel #

92 (42) 35811172, 35711369, 35763431

Fax #

92 (42) 35812052

Email

factory@sizafac.brain.net.pk

 

 

Short Description Of Business

 

a.

Nature of Business

Manufacture & Marketing of Pharmaceutical Products

b.

Year Established

1978

c.

Registration #

0006462

 

 

Branches

 

65/2 Syed Maratib Ali Road,
FCC, Gulberg IV, Lahore,

Pakistan

 

 

Auditors

 

Arshad Raheem & Co.

(Chartered Accountants)

39-Link Farid Kot Road, Lahore, Pakistan

 

 

Legal Status

 

Subject Company was established as a Private Limited Company in 1978

 

6.

Authorized Capital

Rs. 30,000,000/- divided into 300,000 shares of Rs. 100/- each

 

Issued & Paid up Capital

Rs. 16,875,200/- divided into 168,752 shares of Rs. 100/- each

 

 

Details of Directors

 

Names

Nationality

Address

Occupation

Designation

Mr. Khawaja Muhammad Zahid

 

 

Mr. Muhammad Iqbal

 

 

Mr. Muhammad Saboor

 

 

Mr. Muhammad Saeed

 

 

Mr. Muhammad Sadiq

 

 

Mr. Khawaja Raza Zahid

 

 

Mr. Khawaja Muhammad Arif

 

 

Mr. Khawaja Muhammad Asif Razee

Pakistani

 

 

 

Pakistani

 

 

 

Pakistani

 

 

 

Pakistani

 

 

 

Pakistani

 

 

 

Pakistani

 

 

 

Pakistani

 

 

 

Pakistani

18 K.M. Main Ferozepur Road, Lahore

 

18 K.M. Main Ferozepur Road, Lahore

 

18 K.M. Main Ferozepur Road, Lahore

 

18 K.M. Main Ferozepur Road, Lahore

 

18 K.M. Main Ferozepur Road, Lahore

 

18 K.M. Main Ferozepur Road, Lahore

 

18 K.M. Main Ferozepur Road, Lahore

 

18 K.M. Main Ferozepur Road, Lahore

Business

 

 

 

Business

 

 

 

Business

 

 

 

Business

 

 

 

Business

 

 

 

Business

 

 

 

Business

 

 

 

Business

Chief Executive

 

 

 

Director

 

 

 

Director

 

 

 

Director

 

 

 

Director

 

 

 

Director

 

 

 

Director

 

 

 

Director

 

 

Shareholders

 

Names

No. of Shares

Mr. Khawaja Muhammad Zahid

 

Mr. Muhammad Iqbal

 

Mr. Muhammad Saboor

 

Mr. Muhammad Saeed

 

Mr. Muhammad Sadiq

 

Mr. Khawaja Raza Zahid

 

Mr. Khawaja Muhammad Arif

 

Mr. Khawaja Muhammad Asif Razee

 

Mrs. Misbah Arif

24,688

 

19,219

 

26,719

 

19,219

 

19,219

 

17,500

 

36,813

 

1,250

 

4,125

 

 

Associates

 

A.         Subsidiary

 

None

 

 

B.         Associated Companies

 

(1) Lahore Medical Instruments (Pvt) Limited, Pakistan.

 

 

Business Activities

 

Manufacture & marketing of different pharmaceutical class like Anti Biotic, Anti Malarials, Anti-Rheumatic, Antihistamine, Narcotic Analgesic, Non Steroidal Respiratory Anti Inflamatory, Quinolones, Vitamins, Phenothiazine, Hypolipidaemics, Muscle Relaxant, Amoebicide, Calcium-Antagonist, Cardio Selective Beta Blocker with their brand names of ADOLAN, AHYAL, ALEREAS, ALODINE, ALOVAC, AMOR, AMRX, AMYLINE, ANASYNTH, APAROX, AQUASIN, ASMATOL, ASTEMINE, ASTHANIL, AVITA, BIKIL, BISON, CLOPAN, CLOTRIMA, CONVUL, CYPRODIN, DEOCALM, DEVOM, DIABETA, DIPYRON, DUPOPHEN, ELOVIR, EMETIL, EMOTIVAN, EPINAT, GARAN, IMIDOL, INDOCIN, LIMBAR, LIVIAT, LOMPER, LORICIN, LOXAT, MAVEST, MAYADIL, MEGAVIT, METROZIL, MEXAIR, NAUSIN, NEOLOX, NEOSTIG, NIFELAT, NOCTRUM, NUMBAIX, OBRAMYCIN, PARACETAMOL, PRAVA, RANITIDE, RHEUMATIN, ROTAVIT, SAURAN, SIZADOX, SOLVEIN, SOPRA, STYFEN, SUCFATE, WORMAZOLE, XIVAL, ZEEFRA, ZEMYCARD

 

 

Number of Employees

 

180

 

 

Actual Capacity & Production

 

The capacity and production of the Company’s plant is indeterminable as it is multi-product and involves varying processes of manufacture.

 

 

Annual Sales Volume

 

Year

In Pak Rupees

2010

220,000,000/- (Estimated)

 

 

Trade Suppliers (Foreign)

 

(1) BASELL POLYOLEFINS, BELGIUM.

(2) SHADONG PHARMACEUTICALS, CHINA.

 

 

Distributors Network

 

Mainly exist at major cities of Pakistan

 

 

Bankers

 

(1) MCB Bank Limited, Pakistan.

(2) Habib Bank Limited, Pakistan.

(3) Bank Alfalah Limited, Pakistan.

(4) Faysal Bank Limited, Pakistan.

(5) United Bank Limited, Pakistan.

 

 

Memberships

 

Lahore Chamber of Commerce & Industry.(LCCI)

Pakistan Pharmaceutical Manufacturers Association.(PPMA)

 

 

Foreign Exchange Rates

 

Currency

 

Unit

Pakistani Rupee

US Dollar

1

Rs. 94.80

UK Pound

1

Rs. 146.70

Euro

1

Rs. 116.10

 

 

Comments

 

Subject Company was established in 1978 and is engaged in manufacture & marketing of Pharmaceutical Products. Directors are reported as resourceful and experienced businessmen. Trade relations are reported as fair. Subject can be considered for normal business dealings at usual trade terms and conditions.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.54.92

UK Pound

1

Rs.85.47

Euro

1

Rs.67.15

 

 

INFORMATION DETAILS

 

Report Prepared by :

PDT

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.